Ambulatory Blood Pressure Monitoring Devices Market: as guideline bodies keep affirming that a single office reading cannot detect masked or nocturnal hypertension, every clinic that adopts a 24-hour ABPM protocol now converts a one-time office visit into a full diagnostic profile, so demand is moving from cardiology specialists into primary care, and competitive advantage is shifting toward device makers who can prove reimbursement-grade accuracy rather than those who simply sell the most cuffs.

The global ambulatory blood pressure monitoring devices market size was USD 2.15 Billion in 2025 and is expected to register a revenue CAGR of 6.3% during the forecast period. Market revenue growth is driven by factors such as the clinical guideline endorsement of 24-hour ABPM as the diagnostic gold standard, the scale of undiagnosed hypertension globally, and the expansion of CMS remote patient monitoring reimbursement into ambulatory blood pressure protocols. The first driving factor is clinical guideline endorsement of ambulatory monitoring over office-based single measurement. International hypertension guidelines from the European Society of Hypertension and the American Heart Association consistently endorse ambulatory blood pressure monitoring as the clinical gold standard for hypertension diagnosis, citing the superiority of 24-hour BP profiles in detecting masked hypertension, white-coat hypertension, and nocturnal non-dipping patterns. The second driving factor is the scale of undiagnosed hypertension globally. The WHO reported that approximately 1.4 billion adults aged 30 to 79 had hypertension globally in 2024, with approximately 44% of hypertensive adults unaware of their condition. The third driving factor is remote patient monitoring reimbursement expansion, which gives providers a direct billing pathway for ambulatory monitoring data. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single cleared monitoring platform accumulates additional indications on the same installed device base, which converts one clearance into a widening set of billable clinical uses without a new hardware sale. Once a device platform earns its baseline ABPM clearance, each additional cleared feature, such as arrhythmia co-detection during the same 24-hour recording, adds billable clinical value to a monitoring session a provider was already going to run, so revenue per device compounds as the platform's cleared feature set widens around the same cuff and recorder hardware. As a result, demand and revenue share are concentrating around platforms that combine ABPM accuracy with additional cleared cardiac indications, and the forecast tilts toward multi-feature ABPM systems rather than single-purpose 24-hour monitors. For instance, in November 2024, the FDA granted De Novo authorization to Omron Healthcare's blood pressure monitors with AI-powered atrial fibrillation detection, one of a widening set of cardiac indications now running on the same ambulatory monitoring hardware Omron already had in clinical use. These are some of the key factors driving revenue growth of the market.

Because traditional 24-hour cuff-based ABPM systems inflate every 20 to 30 minutes throughout the monitoring period including during sleep, patients experience sleep disruption and arm discomfort that reduces adherence to full 24-hour protocols, so a meaningful share of ABPM recordings are incomplete or require repeat testing.

Cuffless accuracy validation is a second constraint, because photoplethysmography-based cuffless wearables that would solve the comfort problem have not yet consistently demonstrated the same clinical-grade accuracy as cuff-based oscillometric systems, which limits their use to wellness screening rather than diagnostic-grade ambulatory monitoring.

Device and interpretation cost is a third constraint, since dedicated ABPM systems and the physician time required to interpret a full 24-hour recording remain more expensive than a single office reading, so lower-income healthcare markets continue to rely on office-based measurement despite its documented diagnostic limitations.

These factors substantially limit ambulatory blood pressure monitoring devices market growth over the forecast period.

The clearest driver of demand is the guideline-level consensus that ambulatory monitoring, not office-based single measurement, is the reference standard for hypertension diagnosis. Office-based measurement only captures a single moment in time, and masked hypertension, white-coat hypertension, and nocturnal non-dipping patterns by definition require a full 24-hour recording to detect, so any diagnostic pathway limited to office readings will systematically misclassify a meaningful share of patients regardless of how carefully the individual reading is taken. The WHO reported that approximately 1.4 billion adults aged 30 to 79 had hypertension globally in 2024, with approximately 44% of hypertensive adults unaware of their condition, a diagnostic gap that guideline bodies including the European Society of Hypertension and the American Heart Association cite directly when endorsing ambulatory monitoring over office measurement. Omron Healthcare, Spacelabs Healthcare, SunTech Medical, and Baxter International's Welch Allyn all maintain ABPM device portfolios validated against these guideline standards. The effect on the market is that ABPM device procurement is increasingly written into primary care and cardiology clinical protocols rather than being reserved for specialist confirmatory use. These are some of the key factors driving revenue growth of the market.

The second driver is CMS remote patient monitoring reimbursement, which gives providers a direct financial reason to deploy ambulatory and home blood pressure monitoring programmes. RPM reimbursement codes pay providers for reviewing and acting on patient-generated physiological data over a defined monitoring period, so once a clinic enrolls a hypertensive patient in an RPM-billed ambulatory monitoring programme, the ongoing data review itself becomes a billable clinical service rather than a cost absorbed for guideline compliance alone. Withings partnered with CVS Health to distribute FDA-cleared smart blood pressure monitors as part of CVS chronic care RPM kits under CMS remote patient monitoring reimbursement in February 2025, illustrating how retail and pharmacy channels are being built directly around the RPM billing pathway. The effect on the market is that provider adoption decisions increasingly follow reimbursement eligibility rather than device accuracy alone, favouring platforms already integrated into RPM billing workflows. These are some of the key factors driving revenue growth of the market.

The WHO estimates that 44% of hypertensive adults globally remain unaware of their condition. A single office reading cannot close that gap; a 24-hour ambulatory profile can.

The third driver is the early regulatory approval of cuffless, ring-format continuous blood pressure monitoring technology in select international markets. Cuffless ambulatory monitoring works by extracting pulse wave features from an optical sensor rather than mechanically inflating a cuff, and because that approach eliminates the sleep disruption that limits adherence to traditional cuff-based ABPM, regulatory approval of a validated cuffless system directly addresses the market's primary adoption constraint. In September 2025, Sky Labs received approval from South Korea's Ministry of Food and Drug Safety for CART BP, a ring-type cuffless ABPM device enabling 24-hour continuous blood pressure monitoring without a cuff, including during sleep. The effect on the market is that patient adherence to full 24-hour monitoring protocols should improve as cuffless alternatives clear additional regulatory jurisdictions. These are some of the key factors driving revenue growth of the market.

However, the ambulatory blood pressure monitoring devices market faces severe adoption constraints from patient discomfort during traditional cuff-based monitoring and the unresolved accuracy validation gap for cuffless alternatives.

Because traditional 24-hour cuff-based ABPM systems inflate every 20 to 30 minutes throughout the monitoring period including during sleep, patients experience sleep disruption and arm discomfort that reduces adherence to full 24-hour monitoring protocols, and incomplete or invalidated recordings requiring repeat testing add cost and delay to the diagnostic pathway.

Cuffless accuracy validation compounds this, because photoplethysmography-based cuffless wearables that would solve the comfort problem have not yet consistently demonstrated the ISO 81060-2 clinical-grade accuracy standard that cuff-based oscillometric systems meet, so most cuffless devices remain confined to wellness screening rather than diagnostic-grade ambulatory monitoring even where regulatory approval exists in select markets.

Device and interpretation cost is the third constraint, since dedicated ABPM recorder hardware and the physician time required to interpret a full 24-hour recording remain more expensive than a single office reading, so lower-income healthcare markets continue to rely on office-based measurement despite its documented diagnostic limitations.

These factors substantially limit ambulatory blood pressure monitoring devices market growth over the forecast period.

Based on device type, the global ambulatory blood pressure monitoring devices market is segmented into ambulatory blood pressure monitors, home blood pressure monitors, and wearable BP monitors. Ambulatory blood pressure monitors hold the largest revenue share, because clinical guideline endorsement of 24-hour cuff-based ABPM as the diagnostic standard sustains procurement across cardiology, nephrology, and increasingly primary care settings, which suits a market where guideline compliance drives purchasing more than any single feature. Home blood pressure monitors remain established for routine patient self-monitoring and are cheaper per unit than dedicated ABPM systems, but they cannot match the diagnostic-grade 24-hour profile that guideline bodies require for confirmatory hypertension diagnosis. Wearable BP monitors are expected to register the fastest revenue growth rate in the global ambulatory blood pressure monitoring devices market over the forecast period, driven by Sky Labs' September 2025 MFDS-approved CART BP ring-format cuffless device, which is why other cuffless developers are pursuing similar regulatory pathways outside the United States first.

Based on technology, the global ambulatory blood pressure monitoring devices market is segmented into oscillometric automated BP monitors and cuffless and photoplethysmography-based monitors. Oscillometric automated BP monitors hold the largest revenue share, because they remain the only technology validated to the ISO 81060-2 clinical accuracy standard required for diagnostic-grade ambulatory monitoring, which suits a market where clinical validation, not user comfort, has historically determined guideline endorsement. Cuffless and photoplethysmography-based monitors are expected to register the fastest revenue growth rate in the global ambulatory blood pressure monitoring devices market over the forecast period, driven by early regulatory approvals outside the United States such as Sky Labs' MFDS-cleared CART BP, which is why device makers are prioritising non-US regulatory pathways for their cuffless platforms.

Based on end-use, the global ambulatory blood pressure monitoring devices market is segmented into clinics and physician offices, hospitals and acute care, and home healthcare and remote patient monitoring. Clinics and physician offices hold the largest revenue share, because ambulatory monitoring is most commonly prescribed and fitted during a specialist or primary care visit, which ties directly back to the guideline-driven prescribing pattern described in the market's primary demand driver. Home healthcare and remote patient monitoring is expected to register the fastest revenue growth rate in the global ambulatory blood pressure monitoring devices market over the forecast period, driven by CMS RPM reimbursement codes that pay providers for reviewing patient-generated blood pressure data, which is why Withings and CVS Health's RPM-integrated distribution partnership is expanding home-based monitoring access.

Based on regional analysis, the ambulatory blood pressure monitoring devices market in North America accounted for largest revenue share in 2025. The United States leads because CMS remote patient monitoring reimbursement codes give providers a direct billing pathway for ambulatory and home blood pressure data, and because Omron Healthcare, Baxter International, SunTech Medical, and Withings all maintain their primary commercial and regulatory presence in the US market. Omron Corporation reported Healthcare segment revenue of JPY 114.3 Billion, approximately USD 760 Million, in FY2024, anchoring a domestic device infrastructure large enough to sustain multiple competing ABPM platforms simultaneously. The concentration of FDA clearance activity in the country also means new ABPM feature indications are typically launched in the United States first, before expanding to other regulatory jurisdictions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. The European Society of Hypertension's guideline endorsement of ambulatory monitoring as the diagnostic standard has driven longstanding clinical adoption across national health systems, and SCHILLER AG's ABPM product line maintains a strong European institutional presence. The result is steady rather than rapid growth, shaped more by national health system procurement cycles than by underlying patient demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. South Korea and Japan represent two of the most advanced national markets within the region for ABPM technology. South Korea is the earlier-launch market for cuffless ABPM technology in the region, illustrated by Sky Labs' September 2025 MFDS approval for CART BP, which leaves more room for growth than in the already cuff-based-saturated North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with private hospital and cardiology networks driving early ABPM adoption among higher-income patients. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the precision pressure sensors and semiconductor components that Latin American device assemblers depend on, an effect expected to run through 2026 and slow ambulatory monitoring device adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding private hospital network and the UAE's regional distribution hubs represent the primary investment centres for ambulatory monitoring device adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the cardiology and specialist infrastructure needed to support ABPM at scale.